Information for "177LuPSMA Radioligand Care is Advantageous because ThirdLine Treatment of People along with Metastatic CastrationResistant Cancer of prostate A Systematic Review and also Network MetaAnalysis involving Randomized Managed Trial offers"
From EECH Central
Basic information
Display title | 177LuPSMA Radioligand Care is Advantageous because ThirdLine Treatment of People along with Metastatic CastrationResistant Cancer of prostate A Systematic Review and also Network MetaAnalysis involving Randomized Managed Trial offers |
Default sort key | 177LuPSMA Radioligand Care is Advantageous because ThirdLine Treatment of People along with Metastatic CastrationResistant Cancer of prostate A Systematic Review and also Network MetaAnalysis involving Randomized Managed Trial offers |
Page length (in bytes) | 3,557 |
Page ID | 1426156 |
Page content language | English (en) |
Page content model | wikitext |
Indexing by robots | Allowed |
Number of redirects to this page | 0 |
Page protection
Edit | Allow all users (infinite) |
Move | Allow all users (infinite) |
Edit history
Page creator | Israelqueen13 (Talk | contribs) |
Date of page creation | 09:48, 1 May 2024 |
Latest editor | Israelqueen13 (Talk | contribs) |
Date of latest edit | 09:48, 1 May 2024 |
Total number of edits | 1 |
Total number of distinct authors | 1 |
Recent number of edits (within past 90 days) | 1 |
Recent number of distinct authors | 1 |